Beigene Drug Patent Portfolio
Beigene owns 1 orange book drug protected by 12 US patents Given below is the list of Beigene's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11786531 | Methods of treating B-cell proliferative disorder | 19 Jan, 2043 | Active |
| US11896596 | Methods of treating B-cell proliferative disorder | 19 Jan, 2043 | Active |
| US11911386 | Methods of treating B-cell proliferative disorder | 19 Jan, 2043 | Active |
| US11701357 | Treatment of B cell cancers using a combination comprising Btk inhibitors | 24 Jun, 2039 | Active |
| US10927117 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | 15 Aug, 2037 | Active |
| US11591340 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | 15 Aug, 2037 | Active |
| US11851437 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | 15 Aug, 2037 | Active |
| US11884674 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | 15 Aug, 2037 | Active |
| US11970500 | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | 15 Aug, 2037 | Active |
| US10570139 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | 22 Apr, 2034 | Active |
| US11142528 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | 22 Apr, 2034 | Active |
| US9447106 | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators | 22 Apr, 2034 | Active |
Latest Legal Activities on Beigene's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Beigene.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eCofC Notification | 14 May, 2024 | US11786531 |
| Recordation of Patent eCertificate of Correction | 14 May, 2024 | US11786531 |
| Patent eCofC Notification | 14 May, 2024 | US11786531 |
|
Email Notification
Critical
| 14 May, 2024 | US11786531 |
| Mail Certificate of Correction Memo | 04 Apr, 2024 | US11786531 |
| Certificate of Correction Memo | 03 Apr, 2024 | US11786531 |
| Post Issue Communication - Certificate of Correction | 03 Apr, 2024 | US11786531 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Mar, 2024 | US9447106 |
|
Recordation of Patent Grant Mailed
Critical
| 27 Feb, 2024 | US11911386 |
|
Email Notification
Critical
| 27 Feb, 2024 | US11911386 |
| Patent eGrant Notification | 27 Feb, 2024 | US11911386 |
| Mail Patent eGrant Notification | 27 Feb, 2024 | US11911386 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 27 Feb, 2024 | US11911386 |
| Recordation of Patent eGrant | 27 Feb, 2024 | US11911386 |
| Recordation of Patent eGrant | 13 Feb, 2024 | US11896596 |
Beigene's Family Patents
Beigene drugs have patent protection in a total of 28 countries. It's US patent count contributes only to 23.0% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Beigene Drug List
Given below is the complete list of Beigene's drugs and the patents protecting them.
1. Brukinsa
Brukinsa is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11786531 | Methods of treating B-cell proliferative disorder |
19 Jan, 2043
(17 years from now)
| Active |
| US11896596 | Methods of treating B-cell proliferative disorder |
19 Jan, 2043
(17 years from now)
| Active |
| US11911386 | Methods of treating B-cell proliferative disorder |
19 Jan, 2043
(17 years from now)
| Active |
| US11701357 | Treatment of B cell cancers using a combination comprising Btk inhibitors |
24 Jun, 2039
(14 years from now)
| Active |
| US10927117 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
15 Aug, 2037
(12 years from now)
| Active |
| US11591340 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
15 Aug, 2037
(12 years from now)
| Active |
| US11851437 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
15 Aug, 2037
(12 years from now)
| Active |
| US11884674 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
15 Aug, 2037
(12 years from now)
| Active |
| US11970500 | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
15 Aug, 2037
(12 years from now)
| Active |
| US10570139 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
22 Apr, 2034
(8 years from now)
| Active |
| US11142528 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
22 Apr, 2034
(8 years from now)
| Active |
| US9447106 | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
22 Apr, 2034
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brukinsa's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List